MX2010010871A - Compuesto de indolinona. - Google Patents

Compuesto de indolinona.

Info

Publication number
MX2010010871A
MX2010010871A MX2010010871A MX2010010871A MX2010010871A MX 2010010871 A MX2010010871 A MX 2010010871A MX 2010010871 A MX2010010871 A MX 2010010871A MX 2010010871 A MX2010010871 A MX 2010010871A MX 2010010871 A MX2010010871 A MX 2010010871A
Authority
MX
Mexico
Prior art keywords
alkyl
constipation
pharmaceutical composition
activation activity
channel activation
Prior art date
Application number
MX2010010871A
Other languages
English (en)
Inventor
Hidetaka Kaku
Michihito Kageyama
Tomofumi Takuwa
Katsura Nozawa
Hitoshi Doihara
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2010010871A publication Critical patent/MX2010010871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Se proporciona un compuesto A, que es útil como un ingrediente activo para una composición farmacéutica, por ejemplo una composición farmacéutica para tratar el síndrome de intestino irritable de tipo estreñimiento, estreñimiento atónico y/o trastorno gastrointestinal funcional. Los presentes inventores han estudiado ampliamente los compuestos que tienen actividad de activación del canal de TRPA1, y han confirmado que un compuesto de indolinona tiene una actividad de activación del canal de TRPA1, y así completaron la presente invención. El compuesto de indolinona de la presente invención tiene una actividad de activación del canal de TRPA1 y puede utilizarse como un ingrediente activo de una composición farmacéutica para prevenir y/o tratar el síndrome de intestino irritable de tipo estreñimiento, estreñimiento atónico y/o trastorno gastrointestinal funcional o similares.
MX2010010871A 2008-04-01 2009-03-30 Compuesto de indolinona. MX2010010871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008095040 2008-04-01
PCT/JP2009/056431 WO2009123080A1 (ja) 2008-04-01 2009-03-30 インドリノン化合物

Publications (1)

Publication Number Publication Date
MX2010010871A true MX2010010871A (es) 2010-10-26

Family

ID=41135456

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010871A MX2010010871A (es) 2008-04-01 2009-03-30 Compuesto de indolinona.

Country Status (13)

Country Link
US (1) US20110009379A1 (es)
EP (1) EP2261206A4 (es)
JP (1) JPWO2009123080A1 (es)
KR (1) KR20100135248A (es)
CN (1) CN101983188A (es)
AU (1) AU2009232836A1 (es)
BR (1) BRPI0909209A2 (es)
CA (1) CA2720275A1 (es)
IL (1) IL208164A0 (es)
MX (1) MX2010010871A (es)
RU (1) RU2010144548A (es)
WO (1) WO2009123080A1 (es)
ZA (1) ZA201006623B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203715A1 (en) 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
WO2012078519A2 (en) * 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
US9182233B2 (en) * 2012-05-17 2015-11-10 Robert Bosch Gmbh System and method for autocompletion and alignment of user gestures
US10482265B2 (en) * 2015-12-30 2019-11-19 International Business Machines Corporation Data-centric monitoring of compliance of distributed applications
CN113545316B (zh) * 2020-04-24 2022-05-17 中国科学院上海药物研究所 血根碱在制备trpa1通道激动剂中的应用
KR102620902B1 (ko) * 2020-04-24 2024-01-04 가천대학교 산학협력단 신규 알파-시누클레인 방사성 리간드 및 이를 포함하는 신경퇴행성 질환 진단용 조성물
WO2023090313A1 (ja) 2021-11-16 2023-05-25 京都府公立大学法人 摂食量亢進用及び／又は食欲不振改善用組成物並びに一過性受容器電位アンキリン１を活性化するための組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1239553A (es) * 1967-08-16 1971-07-21
US3428649A (en) * 1968-01-23 1969-02-18 Mcneilab Inc Oxindole derivatives
US6340699B1 (en) * 1998-05-01 2002-01-22 Eli Lilly And Company SPLA2 inhibitor compounds for treatment of disease
TWI270545B (en) * 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
JP4897221B2 (ja) 2002-12-20 2012-03-14 チバ ホールディング インコーポレーテッド アミン類の合成及びその合成のための中間体
WO2006105796A1 (en) * 2005-04-08 2006-10-12 Leo Pharma A/S Novel indolinone derivatives
EP1872795A4 (en) * 2005-04-21 2009-07-22 Astellas Pharma Inc THERAPEUTIC AGENT AGAINST IRRITATION SYNDROME
JP2007047770A (ja) * 2005-07-13 2007-02-22 Fujifilm Corp 感光性組成物
EP1744212B1 (en) * 2005-07-13 2012-01-11 FUJIFILM Corporation Photosensitive composition
WO2007062399A2 (en) * 2005-11-23 2007-05-31 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
CA2660704A1 (en) * 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
JP4591599B2 (ja) * 2006-10-06 2010-12-01 アステラス製薬株式会社 消化管運動改善剤スクリーニング法
US20090118503A1 (en) * 2007-06-20 2009-05-07 Kevin Sprott Faah inhibitors

Also Published As

Publication number Publication date
CN101983188A (zh) 2011-03-02
IL208164A0 (en) 2010-12-30
WO2009123080A1 (ja) 2009-10-08
ZA201006623B (en) 2011-11-30
RU2010144548A (ru) 2012-05-10
EP2261206A4 (en) 2011-08-17
CA2720275A1 (en) 2009-10-08
AU2009232836A1 (en) 2009-10-08
US20110009379A1 (en) 2011-01-13
EP2261206A1 (en) 2010-12-15
JPWO2009123080A1 (ja) 2011-07-28
KR20100135248A (ko) 2010-12-24
BRPI0909209A2 (pt) 2015-08-25

Similar Documents

Publication Publication Date Title
MX2010010871A (es) Compuesto de indolinona.
TW200612936A (en) Indole derivatives
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
WO2008107478A8 (en) Quinolinone derivatives as parp and tank inhibitors
MY148634A (en) Pyridazinone derivatives
WO2007041077A3 (en) Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
MX2008010671A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MX2009006630A (es) Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.
WO2007137103A3 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007020213A3 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2009156462A3 (en) Organic compounds
NO20072965L (no) Potentiatorer av glutamatreceptorer
ATE517882T1 (de) Chinolinderivate
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
WO2008036652A3 (en) Amidines as modulators of indoleamine 2,3-dioxygenase
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
NO20082096L (no) Azaindol-2-karboksamidderivativer
WO2006077024A3 (en) 5-aminoindole derivatives
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal